Polyhexamethylene Biguanide (PHMB): An Addendum to Current Topical Antimicrobials
- 0 Comments
- 12309 reads
Chronic wounds are often complex, difficult to heal, and may persist for months or years due to underlying disease processes or complications within the healing process.
Treating chronic wounds requires a multifaceted approach in order to address the underlying pathophysiology while promoting healing of the wound.1–4 Before a wound can close, the wound bed status needs to be addressed to assist in creating an environment conducive to tissue repair. This may require 1) removal of nonviable tissue, 2) maintenance of a moisture balance, 3) resolution of any bacterial imbalance, and 4) removal of impediments to healing at the epidermal margins.4 While each of these require attention, concern with bacterial imbalance in the wound bed has lead to the development and commercialization of a variety of antimicrobial products and therapies.
Bacterial imbalance. When wounds fail to heal or are classified as recalcitrant, one of the factors delaying healing that merits consideration is bacterial load in the wound bed and its effect on the tissue repair process.5,6 All chronic wounds are believed to have some level of bacterial bioburden. Depending on the number of organisms, the level of bacteria in the wound bed may be classified as contaminated, colonized, critically colonized, or infected.4,7 Contamination (the presence of organisms in a wound) and colonization (the proliferation of those organisms) are not routinely treated with oral or systemic antibiotics. Once a wound becomes critically colonized (a level of colonization affecting skin cell proliferation and tissue repair), it may progress to a “classic” infection, which may include erythema, cellulitis, edema, and increases in odor, pain, exudate, white blood cell count, and increased body temperature.8
Delayed closure may suggest the formation of an extracellular polysaccharide matrix film or layer (sometimes called a glycocalyx)9 that shields the bacteria from attack while maintaining the moist environment in which they thrive.10 These colonies of bacteria are called biofilms and are produced by Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, and E coli, among others. The biofilm makes it difficult to eliminate pathogens by requiring as much as 50–1000 times the minimal inhibitory concentration (MIC) of an antibiotic or antiseptic.10
Clinicians may attempt to address the bacterial imbalance by combining treatment modalities. To address infection in the wound bed systemic or oral antibiotics should be considered the first line of therapy, especially in complicated skin infections with clinical signs of cellulitis, leukocytosis, or fever.11 In conjunction with systemic therapy, there are a number of antimicrobial dressings currently on the market indicated for use on infected wounds. Antimicrobial dressings are comprised of a variety of different base materials to which antimicrobial agents are added. The major purported benefits of these dressings are that they may reduce the presence of pathogens and decrease the risk of infection while creating a wound bed that will readily support the normal sequence of wound repair.
Antimicrobial Agents in Wound Care
1. Atiyeh BS, Ioannovich J, Al-Amm CA, El-Musa KA. Management of acute and chronic open wounds: the importance of moist environment in optimal wound healing. Curr Pharm Biotechnol. 2002;3(3):179–195.
2. Enoch S, Harding K. Wound bed preparation: the science behind the removal of barriers to healing. WOUNDS. 2003;15(7):213–229.
3. Falanga V. Wound bed preparation: future approaches. Ostomy Wound Manage. 2003;49(5A Suppl):30–33.
4. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):S1–S28.
5. Junkin J. Failure to thrive in wounds: prevention and early intervention. Infect Control Resource. 2003;1(2):1–6.
6. Motta GJ, Milne CT, Corbett LQ. Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. Ostomy Wound Manage. 2004;50(8):48–62.
7. Kingsley A. The wound infection continuum and its application to clinical practice. Ostomy Wound Manage. 2003;49(7A Suppl):1–7.
8. Ovington L. Bacterial toxins and wound healing. Ostomy Wound Manage. 2003;49(7A Suppl):8–12.
9. Sibbald RG. Topical antimicrobials. Ostomy Wound Manage. 2003;49(5A Suppl):14–18.
10. Mertz PM. Cutaneous biofilms: friend or foe? WOUNDS. 2003;15(5):129–132.
11. Stotts NA. Wound infection: diagnosis and management. In: Bryant RA, ed. Acute and Chronic Wounds: Nursing Management. 2nd ed. St. Louis, MO: Mosby: 2000:179–188.
12. Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM. An in-vitro study of the antimicrobial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulfadiazine cream and a silver coated dressing. Burns. 2004;30(1):35–41.
13. Burrell RE. A scientific perspective on the use of topical silver preparations. Ostomy Wound Manage. 2003;49(5A Suppl):19–24.
14. Drosou A, Falabella A, Kirsner RS. Antiseptics on wounds: an area of controversy. WOUNDS. 2003;15(5):149–166.
15. Tambe SM, Sampath L, Modak SM. In-vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother. 2001;47(5):589–598.
16. Ovington LG. The truth about silver. Ostomy Wound Manage. 2004;50(9A Suppl):1S–10S.
17. Parsons D, Bowler PG, Myles V, Jones S. Silver antimicrobial dressings in wound management: a comparison of antibacterial, physical, and chemical characteristics. WOUNDS. 2005;17(8):222–232.
18. Fox CL, Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974:5(6):582–588.
19. Hohaus K, Vennewald I, Wollina U. Deep mycosis caused by Trichophyton mentagrophytes in a diabetic patient. Mycoses. 2003;46(8):355–357.
20. Thomas S, McCubbin P. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. J Wound Care. 2003;12(3):101–107.
21. Thomas S, McCubbin P. An in-vitro analysis of the antimicrobial properties of 10 silver-containing dressings. J Wound Care. 2003;12(8):305–308.
22. Jones S, Bowler PG, Walker M. Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. WOUNDS. 2005;17(9):263–270.
23. Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg.1999;25(2):89–93.
24. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol. 1998;37(5):390–396.
25. Hughes R, Heaselgrave W, Kilvington S. Acanthamoeba polyphaga strain age and method of cyst production influence the observed efficacy of therapeutic agents and contact lens disinfectants. Antimicrob Agents Chemother. 2003;47(10):3080–3084.
26. Wright JB, Lam K, Olson ME, Burrell RE. Is antimicrobial efficacy sufficient? A question concerning the benefits of new dressings. WOUNDS. 2003;15(5):133–142.
27. Burger RM, Franco RJ, Drlica K. Killing Acanthamoebae with polyaminopropyl biguanide: quantitation and kinetics. Antimicrob Agents Chemother. 1994;38(4):886–888.
28. Hiti K, Walochnik J, Haller-Schober EM, Faschinger C, Aspock H. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Br J Ophthalmol. 2002;86(2):144–146.
29. Barker J, Brown MR, Collier PJ, Farrell I, Gilbert P. Relationship between Legionella pneumophila and Acanthamoeba polyphaga: physiological status and susceptibility to chemical inactivation. Appl Env Microbiol. 1992;58(8):2420–2425.
30. Gilbert P, Das JR, Jones MV, Allison DG. Assessment of resistance towards biocides following the attachment of micro-organisms to, and growth on, surfaces. J Appl Microbiol. 2001;91(2):248–254.
31. Gilbert P, Pemberton D, Wilkinson DE. Synergism within polyhexamethylene biguanide biocide formulations. J Appl Bacteriol. 1990;69(4):593–598.
32. Zhou XF, Markx GH, Pethig R, Eastwood IM. Differentiation of viable and non-viable bacterial biofilms using electrorotation. Biochim Biophys Acta. 1995;1245(1):85–93.
33. Kramer A, Roth B, Müller G, Rudolph P, Klocker N. Influence of the antiseptic agents polyhexanide and octenidine on FL cells and on healing of experimental superficial aseptic wounds in piglets. A double-blind, randomized, stratified, controlled, parallel-group study. Skin Pharmacol Physiol. 2004;17(3):141–146.
34. Broxton P, Woodcock PM, Gilbert P. Binding of some polyhexamethylene biguanides to the cell envelope of Escherichia coli ATCC 8739. Microbios. 1984;41(163):15–22.
35. Broxton P, Woodcock PM, Heatley F, Gilbert P. Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol. 1984;57(1):115–124.
36. Ikeda T, Ledwith A, Bamford CH, Hann RA. Interaction of a polymeric biguanide biocide with phospholipids membranes. Biochim Biophys Acta. 1984;769(1):57–66.
37. Yasuda K, Ohmizo C, Katsu T. Potassium and tetraphenylphosphonium ion-selective electrodes for monitoring changes in the permeability of bacterial outer and cytoplasmic membranes. J Microbiol Methods. 2003;54(1):111–115.
38. Kramer A, Behrens-Baumann W. Prophylactic use of topical anti-infectives in ophthalmology. Ophthalmologica. 1997;211(Suppl 1):68–76.
39. Rosin M, Welk A, Kocher T, Majic-Todt A, Kramer A, Pitten FA. The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol. 2002;29(5):392–399.
40. Petrou-Binder S. PHMB-containing antiseptics ‘may offer alternative’ to iodine perioperative agents, say researchers. Available at: http://www.escrs.org/eurotimes/April2003/phmb.asp.
41. Reitsma AM, Rodeheaver GT. Effectiveness of a new antimicrobial gauze dressing as a bacterial barrier. Mansfield, Mass: Tyco Healthcare Group LP; 2001:1–4.
42. Orr R, Eggleston T, Shelanski MV. Determination of the irritating and sensitizing propensities of Kerlix® A.M.D. antimicrobial gauze dressing on scarified human skin. Mansfield, Mass: Tyco Healthcare Group LP; 2001:1–4.
43. Frankel VH, Serafica GC, Damien CJ. Development and testing of a novel biosynthesized XCell for treating chronic wounds. Surg Technol Int. 2004;12:27–33.
44. Alvarez OA, Patel M, Booker J, Markowitz L. Effectiveness of a biocellulose wound dressing for the treatment of chronic venous leg ulcers: results of a single center randomized study involving 24 patients. WOUNDS. 2004;16(7):224–233.
45. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychological implications. J Am Acad Dermatol. 1994;31(1):49–53.
46. Mulder GD. Cost-effective managed care: gel versus wet-to-dry for debridement. Ostomy Wound Manage. 1995;41(2):68–74.